Strs Ohio Increases Stock Position in Solventum Corporation $SOLV

Strs Ohio grew its position in Solventum Corporation (NYSE:SOLV) by 38.5% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 26,055 shares of the company’s stock after purchasing an additional 7,238 shares during the period. Strs Ohio’s holdings in Solventum were worth $1,976,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in SOLV. Teacher Retirement System of Texas purchased a new stake in Solventum in the 1st quarter valued at about $5,077,000. IFM Investors Pty Ltd increased its position in shares of Solventum by 7.4% during the first quarter. IFM Investors Pty Ltd now owns 27,351 shares of the company’s stock valued at $1,907,000 after acquiring an additional 1,895 shares during the last quarter. Concurrent Investment Advisors LLC purchased a new stake in shares of Solventum during the first quarter valued at approximately $216,000. Envestnet Asset Management Inc. increased its position in shares of Solventum by 7.1% during the first quarter. Envestnet Asset Management Inc. now owns 193,510 shares of the company’s stock valued at $14,714,000 after acquiring an additional 12,881 shares during the last quarter. Finally, Crossmark Global Holdings Inc. increased its position in shares of Solventum by 9.8% during the first quarter. Crossmark Global Holdings Inc. now owns 7,888 shares of the company’s stock valued at $600,000 after acquiring an additional 702 shares during the last quarter.

Solventum Stock Up 0.7%

Solventum stock opened at $68.62 on Wednesday. Solventum Corporation has a 1-year low of $60.70 and a 1-year high of $85.92. The firm has a market capitalization of $11.90 billion, a price-to-earnings ratio of 31.77, a P/E/G ratio of 2.77 and a beta of 0.48. The company has a current ratio of 1.22, a quick ratio of 0.86 and a debt-to-equity ratio of 2.14. The firm has a 50 day simple moving average of $72.23 and a 200 day simple moving average of $72.41.

Solventum (NYSE:SOLV) last released its quarterly earnings data on Thursday, August 7th. The company reported $1.69 earnings per share for the quarter, beating analysts’ consensus estimates of $1.45 by $0.24. The business had revenue of $2.16 billion during the quarter, compared to analyst estimates of $2.12 billion. Solventum had a net margin of 4.52% and a return on equity of 29.93%. Solventum’s revenue was up 3.8% compared to the same quarter last year. During the same period in the previous year, the business earned $1.56 EPS. Solventum has set its FY 2025 guidance at 5.800-5.950 EPS. On average, analysts predict that Solventum Corporation will post 6.58 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the company. Jefferies Financial Group assumed coverage on Solventum in a research report on Thursday, September 11th. They set a “hold” rating and a $80.00 target price for the company. Morgan Stanley upgraded shares of Solventum from an “equal weight” rating to an “overweight” rating and raised their price objective for the stock from $80.00 to $103.00 in a report on Tuesday, July 15th. UBS Group initiated coverage on shares of Solventum in a report on Wednesday, October 1st. They set a “neutral” rating and a $77.00 price objective for the company. Piper Sandler restated an “overweight” rating and set a $94.00 price target (up previously from $87.00) on shares of Solventum in a research note on Friday, August 8th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Solventum in a research note on Thursday, October 30th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $84.89.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.